Our therapeutic innovations are empowering people to live life – fully human.
MannKind Corporation is focused on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
Download our MNKD Corporate Presentation
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease.
Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
press releases
view all newsMinimum 15 minutes delayed. Source:
email alerts
You may automatically receive MannKind Corporation information by email. Please enter your email address and provide your email preference selections. Confirm you are not a robot and click submit.